Príomhoifigeach Cliniciúil
Oifig an Phríomhoifigigh Cliniciúil
Ospidéal Dr Steevens, Lána Steevens
Baile Átha Cliath 8 , D08 W2A8

Chief Clinical Officer
Office of the Chief Clinical Officer
Dr Steevens Hospital, Steevens Lane
Dublin 8, D08 W2A8

www.hse.ie
@hselive
t 01 635 2000
e cco@hse.ie

BY EMAIL ONLY

Deputy Chris Andrews
Dáil Éireann
Leinster House
Kildare Street
Dublin 2

11th October 2022

PQ 48959/ 22- Deputy Chris Andrews -To ask the Minister for Health the status of the provision of Evusheld to immunocompromised patients in Ireland; and if he will make a statement on the matter.

Dear Deputy Andrews,

Thank you for your representation.

Tixagevimab /cilgavimab (Evusheld®): The HSE commissioned the rapid review process for Evusheld® for the pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg, on 9 March 2022.

Following receipt of the rapid review dossier, the National Centre for Pharmacoeconomics (NCPE) completed a Rapid Review assessment of Evusheld® on 11 April 2022. Following this review, a full health technology assessment (HTA) was recommended to assess the clinical effectiveness and cost effectiveness of Evusheld® compared with the current standard of care for this indication.

A full HTA was commissioned by the HSE on 29 April 2022. A full HTA was submitted by the applicant company on 16 August 2022 and the HTA appraisal is ongoing.

The NCPE publishes details on medicines where the HSE has commissioned an assessment on their website. The website is updated at regular intervals and includes assessment outcomes and updates on reimbursement for each individual medicine and indication listed. Further details are available at https://www.ncpe.ie/drugs/tixagevimab-cilgavimab-evusheld-hta-id-22015/

I hope this provides you with assistance.

Yours sincerely

Sharon Hayden
General Manager
Office of the CCO